FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression

Ishitsuka,Asako; Fujine,Etsuko; Mizutani,Yoko; Tawada,Chisato; Kanoh,Hiroyuki; Banno,Yoshiko; Seishima,Mariko

doi:10.3892/ijmm.2014.1882

FTY720 and cisplatin synergistically induce the death of cisplatin-resistant melanoma cells through the downregulation of the PI3K pathway and the decrease in epidermal growth factor receptor expression

Authors:
- Asako Ishitsuka
- Etsuko Fujine
- Yoko Mizutani
- Chisato Tawada
- Hiroyuki Kanoh
- Yoshiko Banno
- Mariko Seishima
View Affiliations

Affiliations: Department of Dermatology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu 501-1194, Japan
Published online on: August 6, 2014 https://doi.org/10.3892/ijmm.2014.1882
Pages: 1169-1174

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sphingosine kinase (SK), a key enzyme in sphingosine-1-phosphate (S1P) synthesis, is known to be overexpressed in various types of cancer cells. The effects of anticancer agents on SK1/S1P signaling have not yet been fully assessed in melanoma cells. In the present study, we investigated the effects of the combination of FTY720, an S1P receptor antagonist, and cisplatin, a DNA-damaging agent, on the induction of the death of human melanoma cells, as well as the molecular mechanisms involved. The viability of various human melanoma cell lines was examined following treatment with anticancer drugs. The cisplatin-resistant SK-Mel-28 and cisplatin-sensitive A375 cell lines were selected for this analysis. Protein expression and apoptotic rates were evaluated by western blot analysis following treatment with cisplatin and/or FTY720. Following treatment with a combination of FTY720 and cisplatin, cell viability significantly decreased and the expression of apoptosis-associated cleaved poly(ADP-ribose) polymerase (PARP) was significantly higher in comparison to treatment with cisplatin alone in the SK-Mel-28 cells. In addition, the combination of FTY720 and cisplatin reduced the protein expression of SK1 and the phosphorylation levels of phosphoinositide 3-kinase (PI3K), Akt and mTOR in the SK-Mel-28 cells; the expression of epidermal growth factor receptor (EGFR) was also markedly reduced. These findings suggest that FTY720 and cisplatin synergistically induce cell death through the downregulation of the PI3K/Akt/mTOR pathway and the decrease in EGFR expression in SK-Mel-28 cells. Thus, the combination of FTY720 and cisplatin may have therapeutic potential for chemotherapy-resistant melanoma, and the effects are likely exerted through the downregulation of S1P signaling.

View Figures

View References

1	Taha TA, Hannun YA and Obeid LM: Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol. 39:113–131. 2006. View Article : Google Scholar : PubMed/NCBI
2	Ogretmen B and Hannun YA: Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer. 4:604–616. 2004. View Article : Google Scholar : PubMed/NCBI
3	Olivera A, Kohama T, Edsall LC, et al: Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol. 147:545–558. 1999. View Article : Google Scholar : PubMed/NCBI
4	Xia P, Wang L, Gamble JR and Vadas MA: Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J Biol Chem. 274:34499–34505. 1999. View Article : Google Scholar : PubMed/NCBI
5	Spiegel S and Milstien S: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 4:397–407. 2003. View Article : Google Scholar : PubMed/NCBI
6	Xia P, Gamble JR, Wang L, et al: An oncogenic role of sphingosine kinase. Curr Biol. 10:1527–1530. 2000. View Article : Google Scholar : PubMed/NCBI
7	Ho JW, Man K, Sun CK, Lee TK, Poon RT and Fan ST: Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma. Mol Cancer Ther. 4:1430–1438. 2005. View Article : Google Scholar : PubMed/NCBI
8	Pchejetski D, Doumerc N, Golzio M, et al: Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther. 7:1836–1845. 2008. View Article : Google Scholar : PubMed/NCBI
9	French KJ, Schrecengost RS, Lee BD, et al: Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res. 63:5962–5969. 2003.PubMed/NCBI
10	Shida D, Takabe K, Kapitonov D, Milstien S and Spiegel S: Targeting SphK1 as a new strategy against cancer. Curr Drug Targets. 9:662–673. 2008. View Article : Google Scholar : PubMed/NCBI
11	Vadas M, Xia P, McCaughan G and Gamble J: The role of sphingosine kinase 1 in cancer: oncogene or non-oncogene addiction? Biochim Biophys Acta. 1781:442–447. 2008. View Article : Google Scholar : PubMed/NCBI
12	Azuma H, Takahara S, Horie S, Muto S, Otsuki Y and Katsuoka Y: Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol. 169:2372–2377. 2003. View Article : Google Scholar : PubMed/NCBI
13	Ubai T, Azuma H, Kotake Y, et al: FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft. Anticancer Res. 27:75–88. 2007.PubMed/NCBI
14	Billich A, Bornancin F, Dévay P, Mechtcheriakova D, Urtz N and Baumruker T: Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem. 278:47408–47415. 2003. View Article : Google Scholar : PubMed/NCBI
15	Wang JD, Takahara S, Nonomura N, Ichimaru N, Toki K and Azuma H: Early induction of apoptosis in androgen-independent prostate cancer cell line by FTY720 requires caspase-3 activation. Prostate. 40:50–55. 1999. View Article : Google Scholar
16	Pereira FV, Arruda DC, Figueiredo CR, et al: FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Clinics (Sao Paulo). 68:1018–1027. 2013. View Article : Google Scholar
17	LaMontagne K, Littlewood-Evans A, Schnell C, et al: Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 66:221–231. 2006. View Article : Google Scholar : PubMed/NCBI
18	Tonelli F, Lim KG, Loveridge C, et al: FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal. 22:1536–1542. 2010. View Article : Google Scholar
19	Sukocheva O, Wadham C, Holmes A, et al: Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1. J Cell Biol. 173:301–310. 2006. View Article : Google Scholar : PubMed/NCBI
20	Shida D, Fang X, Kordula T, et al: Cross-talk between LPA1 and epidermal growth factor receptors mediates up-regulation of sphingosine kinase 1 to promote gastric cancer cell motility and invasion. Cancer Res. 68:6569–6577. 2008. View Article : Google Scholar
21	Paugh BS, Paugh SW, Bryan L, et al: EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells. FASEB J. 22:455–465. 2008. View Article : Google Scholar
22	Nemoto S, Nakamura M, Osawa Y, et al: Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem. 84:10422–10432. 2009. View Article : Google Scholar
23	Kawahara S, Otsuji Y, Nakamura M, et al: Sphingosine kinase 1 plays a role in the upregulation of CD44 expression through extracellular signal-regulated kinase signaling in human colon cancer cells. Anticancer Drugs. 24:473–483. 2013. View Article : Google Scholar
24	Guillermet-Guibert J, Davenne L, Pchejetski D, et al: Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther. 8:809–820. 2009. View Article : Google Scholar : PubMed/NCBI
25	Fuereder T, Hoeflmayer D, Jaeger-Lansky A, et al: Sphingosine kinase 1 is a relevant molecular target in gastric cancer. Anticancer Drugs. 22:245–252. 2011. View Article : Google Scholar : PubMed/NCBI
26	Pchejetski D, Bohler T, Brizuela L, et al: FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 70:8651–8661. 2010. View Article : Google Scholar : PubMed/NCBI
27	Heffernan-Stroud LA, Helke KL, Jenkins RW, De Costa AM, Hannun YA and Obeid LM: Defining a role for sphingosine kinase 1 in p53-dependent tumors. Oncogene. 31:1166–1175. 2012. View Article : Google Scholar : PubMed/NCBI
28	Taha TA, Osta W, Kozhaya L, et al: Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem. 279:20546–20554. 2004. View Article : Google Scholar : PubMed/NCBI
29	Rudolf K, Cervinka M and Rudolf E: Dual inhibition of topoisomerases enhances apoptosis in melanoma cells. Neoplasma. 57:316–324. 2010. View Article : Google Scholar : PubMed/NCBI
30	Liu Y, Deng J, Wang L, et al: S1PR1 is an effective target to block STAT3 signaling in activated B cell-like diffuse large B-cell lymphoma. Blood. 120:1458–1465. 2012. View Article : Google Scholar : PubMed/NCBI
31	Dong YB, Yang HL, Elliott MJ and McMasters KM: Adenovirus-mediated E2F-1 gene transfer sensitizes melanoma cells to apoptosis induced by topoisomerase II inhibitors. Cancer Res. 62:1776–1783. 2002.PubMed/NCBI
32	Kim D, Cheng GZ, Lindsley CW, Yang H and Cheng JQ: Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs. 6:1250–1258. 2005.PubMed/NCBI
33	Meier F, Schittek B, Busch S, et al: The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 10:2986–3001. 2005. View Article : Google Scholar : PubMed/NCBI
34	Sinnberg T, Lasithiotakis K, Niessner H, et al: Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol. 129:1500–1515. 2009. View Article : Google Scholar : PubMed/NCBI
35	Liu X, Powlas J, Shi Y, et al: Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth. Anticancer Res. 24:2697–2704. 2004.PubMed/NCBI
36	Sun SY, Rosenberg LM, Wang X, et al: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 65:7052–7208. 2005. View Article : Google Scholar : PubMed/NCBI
37	Francipane MG and Lagasse E: mTOR pathway in colorectal cancer: an update (Review). Oncotarget. 15:49–66. 2014.
38	Rosa R, Marciano R, Malapelle U, et al: Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res. 19:138–147. 2013. View Article : Google Scholar : PubMed/NCBI